Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-center Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Efficacy and Pharmacokinetics of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

NCT04492488 is registered in ClinicalTrials.gov with Shanghai Miracogen Inc. as lead sponsor.

NCT NCT04492488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04492488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-center Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Efficacy and Pharmacokinetics of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
Lead sponsor
Shanghai Miracogen Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 24, 2021
Completion date
December 31, 2024
Enrollment
129 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic gastric cancer, advanced or metastatic gastroesophageal junction cancer, advanced solid tumors